Hypertriglyceridemia: Clinical Trials

4 trials for Hypertriglyceridemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 active not recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Active not recruiting 4

Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of SHR-1918 In Participants With Hypertriglyceridemia
SHR-1918/ SHR-1918 placebo - Hypertriglyceridemia
Phase 3Active not recruitingBeijing Suncadia Pharmaceuticals Co., Ltd3672026-03-312026-10-20
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Plozasiran Injection - Hypertriglyceridemia
Phase 3Active not recruitingArrowhead Pharmaceuticals7102025-04-092026-10-01
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
Olezarsen - Severe Hypertriglyceridemia
Phase 3Active not recruitingIonis Pharmaceuticals, Inc.8852022-12-132025-12-01
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Metreleptin - Lipodystrophy, Diabetes
Phase 3Active not recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)242014-10-092026-10-27

Narrower conditions

Diabetes Mellitus (1)  ·  Hyperlipidemias (1)  ·  Lipodystrophy (1)

Broader conditions

Dyslipidemias (4)  ·  Lipid Metabolism Disorders (4)  ·  Metabolic Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Hyperlipidemias (3)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Skin Diseases (1)  ·  Skin Diseases, Metabolic (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

metreleptin (1)  ·  olezarsen (1)  ·  plozasiran (1)

Sponsors

Arrowhead Pharmaceuticals (1)  ·  Beijing Suncadia Pharmaceuticals Co., Ltd (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

Countries

United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  China (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  Italy (2)  ·  Lithuania (2)  ·  New Zealand (2)

Top investigators

Rebecca J Brown, M.D. (1)

Results publications

PMID 28324110